Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/23279
Title: Additive effects of the Rho kinase inhibitor Y-27632 and vardenafil on relaxation of the corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure
Authors: UVIN, Pieter 
Albersen, Maarten
Bollen, Ine
FALTER, Maarten 
Weyne, Emmanuel
LINSEN, Loes 
Tinel, Hanna
Sandner, Peter
Bivalacqua, Trinity J.
De Ridder, Dirk J. M. K.
Van der Aa, Frank
BRONE, Bert 
VAN RENTERGHEM, Koenraad 
Issue Date: 2017
Publisher: WILEY-BLACKWELL
Source: BJU INTERNATIONAL, 119(2), p. 325-332
Abstract: Objectives To evaluate the expression of the Rho/Rho-associated protein kinase (ROCK) pathway in the corpus cavernosum of patients with severe erectile dysfunction (ED) compared with healthy human corpus cavernosum, and to test the functional effects of two Rho kinase inhibitors (RKIs) on erectile tissue of patients with severe ED, which did not respond to phosphodiesterase type 5 inhibitors (PDE5Is). Patients and Methods Human corpus cavernosum samples were obtained after consent from men undergoing penile prosthesis implantation (n = 7 for organ bath experiments, n = 17 for quantitative PCR [qPCR]). Potent control subjects (n = 5) underwent penile needle biopsy. qPCR was performed for the expression of RhoA and ROCK subtypes 1 and 2. Immunohistochemistry staining against ROCK and alpha smooth muscle actin (alpha SMA) was performed on the corpus cavernosum of patients with ED. Tissue strips were precontracted with phenylephrine and incubated with 1 mu M of the PDE5I vardenafil or with DMSO (control). Subsequently, increasing concentrations of the RKIs azaindole or Y-27632 were added, and relaxation of tissue was quantified. Results The expression of ROCK1 was unchanged (P > 0.05), while ROCK2 (P < 0.05) was significantly upregulated in patients with ED compared with controls. ROCK1 and ROCK2 protein colocalized with alpha SMA, confirming the presence of this kinase in cavernous smooth muscle cells and/or myofibroblasts. After incubation with DMSO, 10 mu M azaindole and 10 mu M Y-27632 relaxed precontracted tissues with 49.5 +/- 7.42% (P = 0.1470 when compared with vehicle) and 85.9 +/- 10.3% (P = 0.0016 when compared with vehicle), respectively. Additive effects on relaxation of human corpus cavernosum were seen after preincubation with 1 mu M vardenafil. Conclusion The RKI Y-27632 causes a significant relaxation of corpus cavernosum in tissue strips of patients with severe ED. The additive effect of vardenafil and Y-27632 shows that a combined inhibition of Rho-kinase and phosphodiesterase type 5 could be a promising orally administered treatment for severe ED.
Notes: [Uvin, Pieter; Albersen, Maarten; Weyne, Emmanuel; De Ridder, Dirk J. M. K.; Van der Aa, Frank; Van Renterghem, Koenraad] Univ Hosp Leuven, Dept Urol, Herestr 49, B-3000 Leuven, Belgium. [Uvin, Pieter; Van Renterghem, Koenraad] Hasselt Univ, Jessa Hosp, Dept Urol, Hasselt, Belgium. [Uvin, Pieter; Albersen, Maarten; Weyne, Emmanuel; De Ridder, Dirk J. M. K.; Van der Aa, Frank] Katholieke Univ Leuven, Dept Dev & Regenerat, Cluster Organ Syst, Fac Med,Grp Biomed Sci, Leuven, Belgium. [Bollen, Ine; Falter, Maarten; Brone, Bert] Univ Hasselt, Physiol Grp, Hasselt, Belgium. [Linsen, Loes] Univ Biobank Limburg, Jessa Hosp, Hasselt, Belgium. [Tinel, Hanna; Sandner, Peter] Bayer HealthCare, Global Drug Discovery, Wuppertal, Germany. [Tinel, Hanna; Sandner, Peter] Hannover Med Sch, Inst Pharmacol, Hannover, Germany. [Bivalacqua, Trinity J.] Johns Hopkins Med Inst, Dept Urol, James Buchanan Brady Urol Inst, Baltimore, MD 21205 USA.
Keywords: Rho kinase inhibitor; corpus cavernosum; erectile dysfunction; Rho/Rho associated protein kinase (ROCK) pathway; Y-27632; phosphodiesterase type 5 inhibitor;Rho kinase inhibitor; corpus cavernosum; erectile dysfunction; Rho/Rho associated protein kinase (ROCK) pathway; Y-27632; phosphodiesterase type 5 inhibitor
Document URI: http://hdl.handle.net/1942/23279
ISSN: 1464-4096
e-ISSN: 1464-410X
DOI: 10.1111/bju.13691
ISI #: 000392075100023
Rights: BJU International © 2016 BJU International
Category: A1
Type: Journal Contribution
Validations: ecoom 2018
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
uvin 1.pdf
  Restricted Access
Published version656.76 kBAdobe PDFView/Open    Request a copy
submitted manuscript PDF.pdfPeer-reviewed author version4.69 MBAdobe PDFView/Open
Show full item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.